AC Immune Keeps Faith In Alzheimer’s Breakthrough, But Spreads Risk With Parkinson’s Bet
Broadened Pipeline And Prevention Strategy
Interview: The Swiss biotech has endured many Alzheimer’s failures, but has been able to broaden its portfolio and income streams while the search for a breakthrough goes on.
You may also be interested in...
Seattle biotech raised $36m series A in March, now obtains glaucoma and AMD drug candidates along with delivery technology. Alligator, Orion partner on bispecific antibodies for cancer.
Deal Snapshot: The company is looking to expand its pipeline beyond Alzheimer’s, where it hit a speedbump in September with the failure of a tau-targeting drug.
Biogen’s investigational anti-tau antibody gosuranemab has missed its primary efficacy endpoint in a Phase II study in patients with Alzheimer's disease, prompting the end of the trial and termination of the compound’s further clinical development.